Literature DB >> 27214328

Exacerbation risk in severe asthma is stratified by inflammatory phenotype using longitudinal measures of sputum eosinophils.

C J Walsh1, T Zaihra2, A Benedetti3,4,5, C Fugère6, R Olivenstein6, C Lemière7,8, Q Hamid6, J G Martin9.   

Abstract

BACKGROUND: Airway inflammatory phenotyping is increasingly applied to subjects with asthma. However, its relationship to clinical outcomes in difficult asthma is incompletely elucidated.
OBJECTIVE: The goal of our study was to determine the relationship between exacerbation rates and phenotypes of difficult asthma based on the longitudinal measures of sputum eosinophils and neutrophils.
METHODS: Subjects in the longitudinal observational study from two tertiary care centres that completed 1 year of observation and provided at least three sputum samples were classified by inflammatory phenotypes using previously established thresholds. Kaplan-Meier curves and univariable and multivariable Cox proportional hazard models were used to determine the association between inflammatory phenotypes and exacerbation rate.
RESULTS: During the study, 115 exacerbations occurred in 73 severe asthmatic subjects. Subjects with the persistently eosinophilic phenotype had a significantly shorter time to first exacerbation and greater risk of exacerbation over a 1-year period than those with the non-eosinophilic phenotype based on the univariable and multivariable Cox proportional hazard model (hazard ratio [HR], 3.24; 95% confidence interval [CI], 1.35-7.72; adjusted HR, 3.90; 95% CI, 1.34-11.36). No significant differences in time to first exacerbation or exacerbation risk over a 1-year period were observed among the neutrophilic phenotypes.
CONCLUSIONS: The persistent eosinophilic phenotype is associated with increased exacerbation risk compared with the non-eosinophilic phenotype in severe asthma. No differences in time to first exacerbation or exacerbation risk over a 1-year period were detected among neutrophilic phenotypes.
© 2016 John Wiley & Sons Ltd.

Entities:  

Keywords:  asthma exacerbation; biomarkers; longitudinal study; severe asthma

Mesh:

Substances:

Year:  2016        PMID: 27214328     DOI: 10.1111/cea.12762

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  11 in total

1.  Baseline sputum eosinophil + neutrophil subgroups' clinical characteristics and longitudinal trajectories for NHLBI Severe Asthma Research Program (SARP 3) cohort.

Authors:  Annette T Hastie; David T Mauger; Loren C Denlinger; Andrea Coverstone; Mario Castro; Serpil Erzurum; Nijar Jarjour; Bruce D Levy; Deborah A Meyers; Wendy C Moore; Brenda Phillips; Sally E Wenzel; John V Fahy; Elliot Israel; Eugene R Bleecker
Journal:  J Allergy Clin Immunol       Date:  2020-02-05       Impact factor: 10.793

Review 2.  Are We Meeting the Promise of Endotypes and Precision Medicine in Asthma?

Authors:  Anuradha Ray; Matthew Camiolo; Anne Fitzpatrick; Marc Gauthier; Sally E Wenzel
Journal:  Physiol Rev       Date:  2020-01-09       Impact factor: 37.312

3.  Protective effects of glaucocalyxin A on the airway of asthmatic mice.

Authors:  Si Chen; Ying Piao; Yilan Song; Zhiguang Wang; Jingzhi Jiang; Yihua Piao; Li Li; Chang Xu; Liangchang Li; Yongxue Chi; Guihua Jin; Guanghai Yan
Journal:  Open Med (Wars)       Date:  2022-07-07

4.  A bispecific antibody strategy to target multiple type 2 cytokines in asthma.

Authors:  Marie Godar; Kim Deswarte; Karl Vergote; Michael Saunders; Hans de Haard; Hamida Hammad; Christophe Blanchetot; Bart N Lambrecht
Journal:  J Allergy Clin Immunol       Date:  2018-06-08       Impact factor: 10.793

5.  Mixed Sputum Granulocyte Longitudinal Impact on Lung Function in the Severe Asthma Research Program.

Authors:  Annette T Hastie; David T Mauger; Loren C Denlinger; Andrea Coverstone; Mario Castro; Serpil Erzurum; Nizar Jarjour; Bruce D Levy; Deborah A Meyers; Wendy C Moore; Brenda R Phillips; Sally E Wenzel; John V Fahy; Elliot Israel; Eugene R Bleecker
Journal:  Am J Respir Crit Care Med       Date:  2021-04-01       Impact factor: 21.405

Review 6.  Immune responses and exacerbations in severe asthma.

Authors:  Matthew J Camiolo; Sagar L Kale; Timothy B Oriss; Marc Gauthier; Anuradha Ray
Journal:  Curr Opin Immunol       Date:  2021-03-24       Impact factor: 7.268

7.  Sputum cell counts to manage prednisone-dependent asthma: effects on FEV1 and eosinophilic exacerbations.

Authors:  Afia Aziz-Ur-Rehman; Angira Dasgupta; Melanie Kjarsgaard; Frederick E Hargreave; Parameswaran Nair
Journal:  Allergy Asthma Clin Immunol       Date:  2017-04-04       Impact factor: 3.406

8.  Mepolizumab asthma treatment failure due to refractory airway eosinophilia, which responded to benralizumab.

Authors:  Alistair Cook; John Harrington; Jodie L Simpson; Peter Wark
Journal:  Respirol Case Rep       Date:  2021-04-01

9.  ITGB4 deficiency induces mucus hypersecretion by upregulating MUC5AC in RSV-infected airway epithelial cells.

Authors:  Xizi Du; Yu Yang; Ming Yang; Lin Yuan; Leyuan Wang; Mengping Wu; Kai Zhou; Wenkai Li; Yang Xiang; Xiangping Qu; Huijun Liu; Xiaoqun Qin; Chi Liu
Journal:  Int J Biol Sci       Date:  2022-01-01       Impact factor: 6.580

10.  Health care resource utilization and characteristics of patients with eosinophilic asthma in secondary health care in Finland.

Authors:  Mika J Mäkelä; Helene Nordahl Christensen; Antti Karlsson; Sarang Rastogi; Kirsi Kettunen
Journal:  Eur Clin Respir J       Date:  2018-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.